Extensive p-Tau pathology and SDS-stable p-Tau oligomers in Alzheimer's cortical synapses

Brain Pathology

Volumn 22, Issue 6, 2012, Pages 826-833

  Henkins, Kristen M ^a   Sokolow, Sophie ^a   Miller, Carol A ^b   Vinters, Harry V ^a   Poon, Wayne W ^c   Cornwell, Lindsey B ^c   Saing, Tommy ^c   Gylys, Karen Hoppens ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amyloid beta; flow cytometry; pS422 antibody; synaptosome; tau

Indexed keywords

AMYLOID BETA PROTEIN; AT8 ANTIBODY; EPITOPE; OLIGOMER; PHF 1 ANTIBODY; PS422 ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANTIBODY LABELING; ARTICLE; BRAIN SYNAPTOSOME; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SOLUBILIZATION; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; BLOTTING, WESTERN; CEREBRAL CORTEX; FLOW CYTOMETRY; HUMANS; PHOSPHORYLATION; SYNAPSES; SYNAPTOSOMES; TAU PROTEINS;

EID: 84867571146     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2012.00598.x     Document Type: Article

References (34)

1. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT, (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103: 26-35.
2. Bernstein HG, (1997) Tissue kallikrein-like immunoreactive material decorates neuritic plaques of Alzheimer patients. Clin Neuropathol 16: 69-71.
3. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E, (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59: 276-289.
4. Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, et al, (1995) Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14: 671-680.
5. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT, (2010) Caspase activation precedes and leads to tangles. Nature 464: 1201-1204.
6. Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, et al, (2007) The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 282: 31755-31765.
7. Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, Gylys KH, (2008) Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol 172: 1683-1692.
8. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al, (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100: 10032-10037.
9. Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y, (2011) Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol Aging 32: 1-14.
10. Gotz J, Chen F, van Dorpe J, Nitsch RM, (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495.
11. Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM, (2004) Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 165: 1809-1817.
12. Gylys KH, Fein JA, Yang F, Miller CA, Cole GM, (2007) Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol Aging 28: 8-17.
13. Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D, (1997) The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem 68: 430-433.
14. Kayed R, (2010) Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin 6: 931-935.
15. Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, et al, (1996) Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 7: 177-181.
16. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R, (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49: 10039-10041.
17. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A, (2006) Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 54: 197-201.
18. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, et al, (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46: 3856-3861.
19. Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM, (1994) Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 667: 138-142.
20. Nakano H, Kobayashi K, Sugimori K, Shimazaki M, Miyazu K, Hayashi M, Furuta H, (2004) Regional analysis of differently phosphorylated tau proteins in brains from patients with Alzheimer's disease. Dement Geriatr Cogn Disord 17: 122-131.
21. Nixon RA, (2000) A "protease activation cascade" in the pathogenesis of Alzheimer's disease. Ann N Y Acad Sci 924: 117-131.
22. Nixon RA, (2005) Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 26: 373-382.
23. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM, (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281: 39413-39423.
24. Park SY, Ferreira A, (2005) The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci 25: 5365-5375.
25. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, et al, (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 286: 23063-23076.
26. Rapoport SI, (2002) Hydrogen magnetic resonance spectroscopy in Alzheimer's disease. Lancet Neurol 1: 82.
27. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al, (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114: 121-130.
28. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al, (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
29. Sahara N, Maeda S, Murayama M, Suzuki T, Dohmae N, Yen SH, Takashima A, (2007) Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur J Neurosci 25: 3020-3029.
30. Schmid I, Uittenbogaart CH, Giorgi JV, (1991) A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry 12: 279-285.
31. Sokolow S, Henkins KM, Bilousova T, Miller CA, Vinters HV, Poon W, et al, (2011) AD synapses contain abundant Abeta monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging (in press).
32. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK, (2010) Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses. Neurobiol Aging 31: 1145-1152.
33. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM, (2007) Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A 104: 10252-10257.
34. Zhou XW, Li X, Bjorkdahl C, Sjogren MJ, Alafuzoff I, Soininen H, et al, (2006) Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. Neurobiol Dis 22: 657-668.